Solid Earnings May Not Tell The Whole Story For China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294)

Simply Wall StMay 1 20:48 ET

CHINARES PHARMA (03320): China Resources Boya Bio-pharmaceutical Group's net income in the first quarter decreased by 8.22% year-on-year.

Jinwu Financial News | CHINARES PHARMA (03320) announced the first quarter results of China Resources Boya Bio-pharmaceutical Group for 2025, with a Net income of 0.139 billion yuan, a year-on-year decrease of 8.22%, and revenue of 0.536 billion yuan, a year-on-year increase of 19.49%.

Jinwu Financial NewsApr 24 21:14 ET

Liberal Arts Biotech: Report for the first quarter of 2025

SZSIApr 24 12:00 ET · Announcements

China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Stock Falls 7.3% in Past Week as Five-year Earnings and Shareholder Returns Continue Downward Trend

Simply Wall StApr 17 01:50 ET

China Resources Boya Bio-pharmaceutical to Dispose of 80% of Pharmaceutical Manufacturing Subsidiary

MT NewswiresApr 15 00:02 ET

China Resources Boya Bio-pharmaceutical Group (300294.SZ): received the approval notice for drug clinical trials.

On April 13, Gelonghui reported that China Resources Boya Bio-pharmaceutical Group (300294.SZ) announced that it has received the Clinical Trial Approval Notification for subcutaneous injection of human immunoglobulin approved by the National Medical Products Administration (Notification No.: 2025LP01029). Indications: Primary immunoglobulin deficiency disorders, such as X-linked agammaglobulinemia, common variable immunodeficiency, and immunoglobulin G subclass deficiency, etc.

Gelonghui FinanceApr 13 03:59 ET